Key takeaway
In 137 adults with type 2 diabetes, 2 days a week of 500-600 kcal changed HbA1c by -0.3% versus -0.5% with daily 1200-1500 kcal, and the difference (0.2%, 90% CI -0.2% to 0.5%) met the pre-set equivalence margin. Weight loss was similar on average, but equivalence was not shown for weight, and only 97 participants completed the trial.
Study design
Randomised trial
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
The research question
Intermittent energy restriction, in which people eat very little on some days only, is a popular weight-loss approach, but no long-term trials had tested it in type 2 diabetes. The authors tested whether 2 days a week of restriction was as good as continuous daily restriction for blood sugar control and weight loss over 12 months.
Who and how
Randomized noninferiority (equivalence) trial at the University of South Australia in 137 adults with type 2 diabetes, randomized 1:1 to intermittent (n = 70) or continuous (n = 67) energy restriction between April 2015 and September 2017. The intermittent diet was 500-600 kcal/day on 2 nonconsecutive days a week with the usual diet on the other 5; the continuous diet was 1200-1500 kcal/day every day, for 12 months. Medications likely to cause hypoglycemia were reduced at baseline. The primary outcome was change in HbA1c, with equivalence set by a 90% CI margin of ±0.5%; weight loss had a margin of ±2.5 kg.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1HbA1c changed by -0.5% (SEM 0.2%) with continuous and -0.3% (SEM 0.1%) with intermittent restriction (P = 0.65). The between-group difference of 0.2% (90% CI -0.2% to 0.5%) met the criteria for equivalence in the intention-to-treat analysis.
- 2Weight change was -5.0 kg (SEM 0.8) with continuous and -6.8 kg (SEM 0.8) with intermittent restriction (P = 0.25). The difference of -1.8 kg (90% CI -3.7 to 0.07) did not meet the equivalence criteria, nor did fat mass (-1.3 kg, 90% CI -2.8 to 0.2) or fat-free mass (-0.5 kg, 90% CI -1.4 to 0.4).
- 3No significant group differences appeared in final step count, fasting glucose, lipid levels or medication effect score at 12 months, and completers analysis gave the same results.
- 4In the first 2 weeks, hypoglycemic or hyperglycemic events were similar (mean 3.2 versus 4.9 events, P = 0.28), affecting 35% (16 of 46) of participants using sulfonylureas and/or insulin.
Limits & uncertainty
- 1Only 97 of the 137 participants completed the trial, so many results depend on people who dropped out or the intention-to-treat handling of them.
- 2Equivalence was not established for weight or body composition, so the trial cannot say whether the two diets are comparable for weight loss.
- 3The trial was in adults with type 2 diabetes at one Australian university, with a mean BMI of 36.0, so it may not apply to people with lower weights or different settings.
- 4Glucose-lowering medication was adjusted at the start, so the results depend on supervised medication management. This reading is based on the abstract only.
What to take from it
Two low-calorie days a week worked about as well as daily restriction for HbA1c here, which may help people who find daily dieting hard. In people taking sulfonylureas or insulin, hypoglycemia is a real risk, so any change in eating and medication must be planned with your clinician.
Reading your own data
Food logs can show whether your low-calorie days really are about 500-600 kcal, and a CGM or finger-stick log can show how your glucose responds. Weigh yourself on the same scale at the same time of day, and compare weekly averages and your clinic's HbA1c rather than single daily readings.
How to read this evidence
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Importance
Intermittent energy restriction is an alternative weight loss method that is becoming popular; however, to date, there are no long-term clinical trials of intermittent energy restriction in patients with type 2 diabetes.
Objective
To compare the effects of intermittent energy restriction (2 days per week) with those of continuous energy restriction on glycemic control and weight loss in patients with type 2 diabetes during a 12-month period.
Design, setting, and participants
Adult participants (N = 137) with type 2 diabetes were randomized 1:1 to parallel diet groups (intermittent energy restriction [n = 70] or continuous energy restriction [n = 67]) between April 7, 2015, and September 7, 2017, at the University of South Australia. Medications likely to cause hypoglycemia were reduced at baseline according to the medication management protocol.
Interventions
An intermittent energy restriction diet (500-600 kcal/d) followed for 2 nonconsecutive days per week (participants followed their usual diet for the other 5 days) or a continuous energy restriction diet (1200-1500 kcal/d) followed for 7 days per week for 12 months.
Main outcomes and measures
The primary outcome was change in hemoglobin A1c (HbA1c) level, with equivalence prespecified by a 90% CI margin of ±0.5%. The secondary outcome was weight loss with equivalence set at ±2.5 kg (±1.75 kg for fat mass loss and ±0.75 kg for fat-free mass loss). All other outcomes were tested for superiority.
Results
Of the 137 randomized participants (77 women and 60 men; mean [SD] age, 61.0 [9.1] years; mean [SD] body mass index, 36.0 [5.8] [calculated as weight in kilograms divided by height in meters squared]; and mean [SD] HbA1c level, 7.3% [1.3%]), 97 completed the trial. Intention-to-treat analysis showed similar reductions in mean (SEM) HbA1c level between the continuous and intermittent energy restriction groups (-0.5% [0.2%] vs -0.3% [0.1%]; P = .65), with a between-group difference of 0.2% (90% CI, -0.2% to 0.5%) meeting the criteria for equivalence. Mean (SEM) weight change was similar between the continuous and intermittent energy restriction groups (-5.0 [0.8] kg vs -6.8 [0.8] kg; P = .25), but the between-group difference did not meet the criteria for equivalence (-1.8 kg; 90% CI, -3.7 to 0.07 kg), nor did the between-group difference in fat mass (-1.3 kg; 90% CI, -2.8 to 0.2 kg) or fat-free mass (-0.5 kg; 90% CI, -1.4 to 0.4 kg). There were no significant differences between groups in final step count, fasting glucose levels, lipid levels, or total medication effect score at 12 months. Effects did not differ using completers analysis. Hypoglycemic or hyperglycemic events in the first 2 weeks of treatment were similar between the continuous and intermittent energy restriction groups (mean number [SEM] of events, 3.2 [0.7] vs 4.9 [1.4]; P = .28), affecting 35% of participants (16 of 46) using sulfonylureas and/or insulin.
Conclusions and relevance
Intermittent energy restriction is an effective alternative diet strategy for the reduction of HbA1c and is comparable with continuous energy restriction in patients with type 2 diabetes.
Trial registration
anzctr.org.au Identifier: ACTRN12615000383561.
Sources & attribution
Effect of Intermittent Compared With Continuous Energy Restricted Diet on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Noninferiority Trial.
Carter S, Clifton PM, Keogh JB.
JAMA network open · 2018-07-06
DOI: 10.1001/jamanetworkopen.2018.0756 ↗PubMed · 30646030 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

